We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNA Acts as Tumor Suppressor in Mouse Lung Cancer Model

By LabMedica International staff writers
Posted on 16 Dec 2009
MicroRNA (mRNA) have been found to act as a tumor suppressors and may form the basis for a new generation of anticancer drugs. More...
MicroRNAs (miRNAs) are small, noncoding RNA molecules that occur naturally in human cells.

Misregulation of these critical cellular components is a frequent event in the development of genetically manifested human diseases such as cancer.

Investigators at Yale University (New Haven, CT, USA) and their colleagues at Mirna Therapeutics (Austin, TX, USA) have been working with the let-7 family of mRNAs. In the current study, they examined the link between let-7 and non-small-cell lung cancer (NSCLC) in a mouse model.

Results published in the December 7, 2009, online edition of the journal Oncogene revealed that let-7 acted as a tumor suppressor, since loss of let-7 function enhanced lung tumor formation. Treatment of mice with existing tumors with let-7 reduced the number and size of the tumors by almost two-thirds.

"This is the first time anybody has shown a positive effect of microRNAs in shrinking lung cancer," said senior author Dr. Frank Slack, professor of molecular, cellular, and developmental biology at Yale University. "We hope it will be valuable in the treatment of many other forms of cancer."

The investigators are now conducting studies to determine whether let-7 therapy in combination with chemotherapy and radiation can induce full remission.

Related Links:
Yale University
Mirna Therapeutics


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.